CBU
ALLO icon

CIBC Bancorp USA’s Allogene Therapeutics ALLO Stock Holding History

CIBC Bancorp USA’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.5K Buy
+14,653
New +$32.2K ﹤0.01% 1908
2025
Q3 		$20K Buy
+16,163
New +$19.3K ﹤0.01% 1454

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

CIBC Bancorp USA's ALLO Position: Q2 2026 in Review

CIBC Bancorp USA opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 14,653 shares worth $30.5K. The stake represents ﹤0.01% of the portfolio and ranks #1908 among its holdings. This is a return to the name: CIBC Bancorp USA previously reported a position in ALLO as recently as Q3 2025.

CIBC Bancorp USA first reported a position in ALLO in Q3 2025 and has held it in 2 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • CIBC Bancorp USA held 14,653 shares of Allogene Therapeutics worth $30.5K as of Q2 2026.
  • Allogene Therapeutics was a new CIBC Bancorp USA position in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1908 holding.
  • CIBC Bancorp USA first reported a position in Allogene Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.